DOTBIO
DotBio develops multi-functional antibodies based on its proprietary DotBody technology as the next generation of cancer therapies. DotBio develops antibody therapies that target, at multiple junctions, the interplay between tumors and the tumor microenvironment to re-establish an effective immune response. Our proprietary technologies enable the rapid generation of multi-specific antibodies targeting multiple processes. The rapid testing of combinatorial ensembles of multi-specific antibody prototypes can directly identify molecules re-activating the tumor immune response with novel synergistic mechanisms.
DOTBIO
Social Links:
Industry:
Biotechnology Life Science Medical
Founded:
2017-01-01
Address:
Singapore, Central Region, Singapore
Country:
Singapore
Website Url:
http://www.dotbiopharma.com
Total Employee:
1+
Status:
Active
Contact:
+65 6906 0743
Email Addresses:
[email protected]
Total Funding:
2.48 M USD
Technology used in webpage:
SPF Google Apps For Business Squarespace Hosted Google DNS Google Domains Google Cloud DNS
Current Employees Featured
Founder
Investors List
Enterprise Singapore
Enterprise Singapore investment in Grant - DotBio
Official Site Inspections
http://www.dotbiopharma.com
- Host name: 198.49.23.145
- IP address: 198.49.23.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "DotBio"
DotBio - Crunchbase Company Profile & Funding
DotBio develops multi-functional antibodies based on its proprietary DotBody technology as the …See details»
Team — DotBio
Ignacio Asial, PhD MSc MEng Founder and CEO . Kelly Hew, PhD Chief Operating Officer . …See details»
DotBio Company Profile 2024: Valuation, Funding & Investors
DotBio General Information Description. Developer of antibody therapies designed to address …See details»
Technology — DotBio
DotBio is a biopharmaceutical company specialized in next-generation antibody therapies. …See details»
DotBio Company Profile - Office Locations, Competitors, Revenue …
DotBio has 5 employees at their 1 location and $2.5 m in total funding,. See insights on DotBio …See details»
DotBio - Products, Competitors, Financials, Employees, …
About DotBio. DotBio is a biopharmaceutical company focused on next-generation antibody …See details»
Pre-A Financing Led By Multiple Specialist Life Science Investors
DotBio, a biopharma company specialized in next-generation antibody therapeutics with a …See details»
Biotech startup DotBio raises US$5.6 million pre-Series A round
Aug 7, 2023 SEEDS Capital-backed biopharmaceutical company DotBio has raised US$5.6 …See details»
BioCentury - Connecting the DotBodies
Aug 1, 2018 Cancer play DotBio Pte. Ltd. launched this week with a screening platform to …See details»
Dotbio emerges with $5.6M pre-series A to advance ... - BioWorld
Aug 9, 2023 Emerging from stealth mode, new immuno-oncology company Dotbio Pte. Ltd. …See details»
Press Release Gastrotech Acquisition - SEC.gov
Www.dorbiopharma.com. DOR BioPharma Executes Letter of Intent for . Acquisition of …See details»
The end of the R&D organization as we know it – Pharma’s ... - STAT
Aug 20, 2021 Each biopharma R&D organization is different in scale, scientific platform …See details»
pressreleasebuhrman.htm - SEC.gov
This press release contains forward-looking statements, within the meaning of Section 21E of …See details»
Pipeline — DotBio
DotBio is developing an internal pipeline of innovative, multi-functional antibody therapies to …See details»
DOR BioPharma, Inc. | LinkedIn
DOR BioPharma, Inc. ( DOR ) is a late-stage biopharmaceutical company developing products …See details»
DOR BioPharma - Overview, News & Similar companies - ZoomInfo
View DOR BioPharma (www.dorbiopharma.com) location in New Jersey, United States , …See details»
DOR BioPharma, Inc. Obtains Fast Track Designation for ... - BioSpace
Jan 6, 2009 DOR BioPharma, Inc. (DOR or the Company) (OTCBB: DORB) today announced …See details»
DOR BioPharma Announces Management Changes - Business Wire
Jul 9, 2004 DOR BioPharma, Inc. Keith Thornton, 305-534-3383 (Investor Relations) …See details»
How biopharma companies can change their business model | BCG
Dec 9, 2021 BCG delivers solutions through leading-edge management consulting, …See details»